111 related articles for article (PubMed ID: 25961552)
1. NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Hou SQ; Liu L
Front Biosci (Landmark Ed); 2015 Jun; 20(7):1179-89. PubMed ID: 25961552
[TBL] [Abstract][Full Text] [Related]
2. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice.
Chen Y; Li YH; Chen XP; Gong LM; Zhang SP; Chang ZJ; Zhang XF; Fu XY; Liu L
Cancer Res; 2005 Dec; 65(23):10838-46. PubMed ID: 16322230
[TBL] [Abstract][Full Text] [Related]
3. The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions.
Li YH; Zhong S; Rong ZL; Ren YM; Li ZY; Zhang SP; Chang Z; Liu L
Biochem Biophys Res Commun; 2007 May; 356(2):444-9. PubMed ID: 17367757
[TBL] [Abstract][Full Text] [Related]
4. NOK/STYK1 interacts with GSK-3β and mediates Ser9 phosphorylation through activated Akt.
Li J; Wu F; Sheng F; Li YJ; Jin D; Ding X; Zhang S
FEBS Lett; 2012 Nov; 586(21):3787-92. PubMed ID: 23010592
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Orang AV; Safaralizadeh R; Hosseinpour Feizi MA; Somi MH
Asian Pac J Cancer Prev; 2014; 15(16):6685-9. PubMed ID: 25169509
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia.
Kondoh T; Kobayashi D; Tsuji N; Kuribayashi K; Watanabe N
Exp Hematol; 2009 Jul; 37(7):824-30. PubMed ID: 19409952
[TBL] [Abstract][Full Text] [Related]
7. A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice.
Liu L; Yu XZ; Li TS; Song LX; Chen PL; Suo TL; Li YH; Wang SD; Chen Y; Ren YM; Zhang SP; Chang ZJ; Fu XY
Cancer Res; 2004 May; 64(10):3491-9. PubMed ID: 15150103
[TBL] [Abstract][Full Text] [Related]
8. STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I.
Zhou C; Qian X; Hu M; Zhang R; Liu N; Huang Y; Yang J; Zhang J; Bai H; Yang Y; Wang Y; Ali D; Michalak M; Chen XZ; Tang J
Autophagy; 2020 Oct; 16(10):1786-1806. PubMed ID: 31696776
[TBL] [Abstract][Full Text] [Related]
9. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
Kimbro KS; Duschene K; Willard M; Moore JA; Freeman S
Mol Biol Rep; 2008 Mar; 35(1):23-7. PubMed ID: 17415682
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.
Shi W; Fu Y; Wang Y
Oncol Lett; 2021 Jul; 22(1):527. PubMed ID: 34055092
[TBL] [Abstract][Full Text] [Related]
11. NOK/STYK1 promotes the genesis and remodeling of blood and lymphatic vessels during tumor progression.
Liu Y; Li T; Hu D; Zhang S
Biochem Biophys Res Commun; 2016 Sep; 478(1):254-259. PubMed ID: 27444381
[TBL] [Abstract][Full Text] [Related]
12. NOK associates with c-Src and promotes c-Src-induced STAT3 activation and cell proliferation.
Wang Y; Liu S; Jiang G; Zhai W; Yang L; Li M; Chang Z; Zhu B
Cell Signal; 2020 Nov; 75():109762. PubMed ID: 32871210
[TBL] [Abstract][Full Text] [Related]
13. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
[TBL] [Abstract][Full Text] [Related]
14. Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice.
Yang Y; Liu L; Tucker HO
Biochem Biophys Res Commun; 2022 Oct; 626():51-57. PubMed ID: 35970044
[TBL] [Abstract][Full Text] [Related]
15. NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes.
Ding X; Jiang QB; Li R; Chen S; Zhang S
Biochem Biophys Res Commun; 2012 May; 421(3):468-73. PubMed ID: 22516751
[TBL] [Abstract][Full Text] [Related]
16. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Lai Y; Zhang Z; Li J; Li W; Huang Z; Zhang C; Li X; Zhao J
Biochem Biophys Res Commun; 2019 Nov; 519(4):659-666. PubMed ID: 31542233
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling.
Li YH; Wang YY; Zhong S; Rong ZL; Ren YM; Li ZY; Zhang SP; Chang ZJ; Liu L
Mol Cells; 2009 Jan; 27(1):39-45. PubMed ID: 19214432
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of Serine Threonine Tyrosine Kinase 1 (STYK1) Inhibits the Migration and Tumorigenesis in Glioma Cells.
Zhou J; Wang F; Liu B; Yang L; Wang X; Liu Y
Oncol Res; 2017 Jul; 25(6):931-937. PubMed ID: 27983928
[TBL] [Abstract][Full Text] [Related]
19. STYK1/NOK affects cell cycle late mitosis and directly interacts with anaphase-promoting complex activator CDH1.
Zeng SL; Patel SS; Lv MQ; Zhu D; Shen WH; Liu L
Heliyon; 2022 Dec; 8(12):e12058. PubMed ID: 36506394
[TBL] [Abstract][Full Text] [Related]
20. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
